The mission is: - ensure the support of CD27
in coordination work with key partners, Rector, Eple, - complete physical inventory work equipment in and EPLE analyze, - to define missions calibration (1 st and 2 e ) level - support the creation and formation of an internal team that can provide support and maintenance, - conduct a scoping note for the elected and the General Management, - Develop a master plan digital in EPLE
Preclinical data demonstrate that SGN-70 blocks the interaction between CD70 and its receptor, CD27
, and selectively depletes activated CD70-positive lymphocytes.
SGN-70 has been shown in preclinical models to selectively deplete CD70-positive lymphocytes and block the co-stimulation pathway between CD70 and its receptor, CD27
Promising and possible biomarkers: type I interferon, sVCAM-1, CD27
high plasma cells, soluble IL-2 receptor, BLyS.
with the appropriate monoclonal antibody has proven highly effective at promoting anti-cancer immunity and we look forward to translating these results to patients.
CDX-1127 is a human monoclonal antibody that targets CD27
Showed that human anti-CD27
mAb inhibited the growth of human tumor cells expressing CD27
in a mouse tumor model.
to develop human antibodies towards CD27
, a potentially important target for immunotherapy of various cancers.
Studies demonstrated that targeting CD27
receptors with Celldex's human anti-CD27
antibodies can increase the numbers of responding T cells and directly impact tumor cells expressing CD27
In analyzing the data from the trial we sought to detect immune correlates by using multi-parametric flow cytometry to identify 16 unique RCC antigen reactive CTL subsets based on the expression of the surface markers CD28, CD45RA, CD27
and CCR7, present in blood draws collected prior to treatment with AGS-003 or sunitinib and after administration of five doses of AGS-003 in combination with sunitinib.
Nasdaq: CLDX) announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No: 8,481,029 entitled "Human immune therapies using a CD27
agonist alone or in combination with other immune modulators" which broadly supports the Company's product candidate CDX-1127.
CDX-1127 has a dual mechanism of action - the antibody can function as an immune modulator through activation of T cells and natural killer cells and it can also function as a conventional antibody by direct activity against tumor cells that express CD27